Friday, 17 Jan 2020

You are here

Taltz FDA Approved for Ankylosing Spondylitis (Radiographic Axial SpA)

The FDA has approved the IL-17A inhibitor Taltz (ixekizumab) for the treatment of adults with active ankylosing spondylitis (AS: also known as radiographic axial spondyloarthritis).  

The recommended dose is 160 mg SC (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks.  The updated package insert can be found here.

According to Lilly, there are 1.6 million people in the US with ankylosing spondylitis, but only 15% of patients with the condition are taking biologic therapies.

Approval is based on the COAST trials in AS. The COAST-V trial studied IXE in biologic naive AS/SpA patients and the COAST-W trial involved patients previously to TNF inhibitors.

In COAST-V, IXE achieved ASAS40 of 48%, compared with 18% of placebo (P < .0001) treated patients. ASAS40 response rates in COAST-W were 25% with ixekizumab vs 13% with placebo (P <0.05).

There are no serious "boxed" warnings.  Other warnings and precautions include:

  • Serious infections
  • Tuberculosis (TB): Evaluate for TB prior to initiating treatment
  • Hypersensitivity: If a serious allergic reaction occurs, discontinue TALTZ
  • Inflammatory Bowel Disease: Crohn’s disease and ulcerative colitis, including exacerbations, occurred in clinical trials

Ixekizumab (IXE) was previously \approved in March 2016 for plaque psoriasis and in December 2017 for psoriatic arthritis.

This will be the second IL-17 targeted biologic (along with Cosentyx) approved by the FDA for ankylosing spondylitis.

 

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Taltz Shines in Non-Radiographic Axial Spondyloarthritis

Ixekizumab (IXE), an interleukin-17A (IL-17A) inhibitor, was recently approved for use in ankylosing spondylitis (also known as radiographic axial spondyloarthritis- axSpA). Lancet has published the results of the COAST-X study showing that ixekizumab was effective in patients with non-radiographic axial spondyloarthritis.

Best of 2019 - SEAM-PsA Study - Does Monotherapy MTX Win Despite Losing to Etanercept in Psoriatic Arthritis?

The SEAM-PsA study examined the efficacy of methotrexate monotherapy, etanercept monotherapy or the combination of MTX and ETN in psoriatic arthritis patients, and found that ETN monotherapy was equivalent to combination therapy - and that both were superior to MTX alone in clinical (ACR and MDA) and radiographic responses.

Best of 2019 - ACR/SPARTAN Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

The American College of Rheumatology (ACR), in partnership with the Spondylitis Association of America (SAA) and the Spondyloarthritis Research and Treatment Network (SPARTAN), released the 2019 Update of the Recommendations for the Treatment of Ankylosing Spondylitis (AS) and Nonradiographic Axial Spondyloarthritis (nr-axSpA).

Upadacitinib Effective in Ankylosing Spondylitis

Lancet reports that the selective JAK1 inhibitor, upadacitinib, was effective when given to patients with active ankylosing spondylitis.

Secukinumab Improves Enthesitis

Secukinumabs (SEC) effect on enthesitis in psoriatic arthritis (PsA) was studied in the FUTURE 2 and 3 studies and SEC was shown significantly reduced enthesitis by more than 65% within 14 week.